FDG PET and PET/CT in the Management of Pediatric Lymphoma Patients

PET Clinics

Volumn 3, Issue 4, 2008, Pages 621-634

  Cheng, Gang ^a   Servaes, Sabah ^a   Alavi, Abass ^a   Zhuang, Hongming ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

FDG; Lymphoma; Pediatric; PET; PET CT

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GALLIUM CITRATE GA 67;

BONE MARROW BIOPSY; CANCER RADIOTHERAPY; CANCER STAGING; CHILDHOOD CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG RESPONSE; ECHOGRAPHY; HEALTH CARE COST; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 67650921096     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2009.04.004     Document Type: Review

References (59)

1. Depas G., De Barsy C., Jerusalem G., et al. 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 32 (2005) 31-38
2. Jerusalem G., Hustinx R., Beguin Y., et al. Evaluation of therapy for lymphoma. Semin Nucl Med 35 (2005) 186-196
3. Seam P., Juweid M.E., and Cheson B.D. The role of FDG-PET scans in patients with lymphoma. Blood 110 (2007) 3507-3516
4. Kasamon Y.L., Jones R.J., and Wahl R.L. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 48 S1 (2007) 19-27S
5. Kirby A.M., and Mikhaeel N.G. The role of FDG PET in the management of lymphoma: what is the evidence base?. Nucl Med Commun 28 (2007) 335-354
6. Montravers F., McNamara D., Landman-Parker J., et al. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 29 (2002) 1155-1165
7. Hernandez-Pampaloni M., Takalkar A., Yu J.Q., et al. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol 36 (2006) 524-531
8. Miller E., Metser U., Avrahami G., et al. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr 30 (2006) 689-694
9. Hampson F.A., and Shaw A.S. Response assessment in lymphoma. Clin Radiol 63 (2008) 125-135
10. Tatsumi M., Cohade C., Nakamoto Y., et al. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 237 (2005) 1038-1045
11. Moog F., Bangerter M., Diederichs C.G., et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206 (1998) 475-481
12. Foo S.S., Mitchell P.L., Berlangieri S.U., et al. Positron emission tomography scanning in the assessment of patients with lymphoma. [see comment]. Intern Med J 34 (2004) 388-397
13. Lin P., Chu J., Kneebone A., et al. Direct comparison of 18F-fluorodeoxyglucose coincidence gamma camera tomography with gallium scanning for the staging of lymphoma. Intern Med J 35 (2005) 91-96
14. Mody R.J., Bui C., Hutchinson R.J., et al. Comparison of (18)F Flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. Leuk Lymphoma 48 (2007) 699-707
15. Rini J.N., Nunez R., Nichols K., et al. Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin's disease. Pediatr Radiol 35 (2005) 169-178
16. Hines-Thomas M., Kaste S.C., Hudson M.M., et al. Comparison of gallium and PET scans at diagnosis and follow-up of pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 51 (2008) 198-203
17. Allen-Auerbach M., Quon A., Weber W.A., et al. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 6 (2004) 411-416
18. Raanani P., Shasha Y., Perry C., et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?. Ann Oncol 17 (2006) 117-122
19. Rodriguez-Vigil B., Gomez-Leon N., Pinilla I., et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 47 (2006) 1643-1648
20. la Fougere C., Pfluger T., Schneider V., et al. Restaging of patients with lymphoma. Comparison of low dose CT (20 mAs) with contrast enhanced diagnostic CT in combined [18F]-FDG PET/CT. Nucl Med 47 (2008) 37-42
21. Bar-Sever Z., Keidar Z., Ben-Barak A., et al. The incremental value of 18F-FDG PET/CT in paediatric malignancies. [see comment]. Eur J Nucl Med Mol Imaging 34 (2007) 630-637
22. Buchmann I., Reinhardt M., Elsner K., et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 91 (2001) 889-899
23. Buchmann I., Neumaier B., Schreckenberger M., et al. [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations-a pilot study. Cancer Biother Radiopharm 19 (2004) 436-442
24. Hicks R.J., Mac Manus M.P., and Seymour J.F. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 35 (2005) 165-175
25. Allen-Auerbach M., de Vos S., and Czernin J. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am 46 (2008) 199-211
26. Hermann S., Wormanns D., Pixberg M., et al. Staging in childhood lymphoma: differences between FDG-PET and CT. Nucl Med 44 (2005) 1-7
27. Amthauer H., Furth C., Denecke T., et al. FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up. Klin Padiatr 217 (2005) 327-333
28. Kabickova E., Sumerauer D., Cumlivska E., et al. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease. Eur J Nucl Med Mol Imaging 33 (2006) 1025-1031
29. Furth C., Denecke T., Steffen I., et al. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease. J Pediatr Hematol Oncol 28 (2006) 501-512
30. Korholz D., Kluge R., Wickmann L., et al. Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences for the GPOH-HD 2003 protocol. Onkologie 26 (2003) 489-493
31. Korholz D., Claviez A., Hasenclever D., et al. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 216 (2004) 150-156
32. Sweetenham J.W. Minimizing late effects in children and adults with Hodgkin lymphoma - the beginning of the end for radiation therapy. [comment]. Leuk Lymphoma 49 (2008) 839-840
33. Schoder H., and Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin North Am 46 (2008) 225-241
34. Haioun C., Itti E., Rahmouni A., et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106 (2005) 1376-1381
35. Hutchings M., Loft A., Hansen M., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 (2006) 52-59
36. Kasamon Y.L., and Wahl R.L. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol 20 (2008) 206-219
37. MacManus M.P., Seymour J.F., and Hicks R.J. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging 7 (2007) 10-18
38. Querellou S., Valette F., Bodet-Milin C., et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 85 (2006) 759-767
39. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579-586
40. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25 (2007) 571-578
41. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. [see comment]. N Engl J Med 339 (1998) 1506-1514
42. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. [see comment]. N Engl J Med 329 (1993) 987-994
43. Nasr A., Stulberg J., Weitzman S., et al. Assessment of residual posttreatment masses in Hodgkin's disease and the need for biopsy in children. J Pediatr Surg 41 (2006) 972-974
44. Zijlstra J.M., Lindauer-van der Werf G., Hoekstra O.S., et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 91 (2006) 522-529
45. Terasawa T., Nihashi T., Hotta T., et al. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. [see comment]. J Nucl Med 49 (2008) 13-21
46. Edeline V., Bonardel G., Brisse H., et al. Prospective study of 18F-FDG PET in pediatric mediastinal lymphoma: a single center experience. Leuk Lymphoma 48 (2007) 823-826
47. Dittmann H., Sokler M., Kollmannsberger C., et al. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 8 (2001) 1393-1399
48. Rhodes M.M., Delbeke D., Whitlock J.A., et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 28 (2006) 300-306
49. Levine J.M., Weiner M., and Kelly K.M. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. [see comment]. J Pediatr Hematol Oncol 28 (2006) 711-714
50. Meany H.J., Gidvani V.K., and Minniti C.P. Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 48 (2007) 399-402
51. Kubota K., Itoh M., Ozaki K., et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 28 (2001) 696-703
52. Xiu Y., Bhutani C., Dhurairaj T., et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 32 (2007) 101-105
53. Zhuang H., Pourdehnad M., Lambright E.S., et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42 (2001) 1412-1417
54. Conrad G.R., and Sinha P. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy. Nucl Med Commun 24 (2003) 1129-1137
55. Lai C.H., Huang K.G., See L.C., et al. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography. Cancer 100 (2004) 544-552
56. Zytoon A.A., Murakami K., El-Kholy M.R., et al. Positron emission tomography and breast lesions: low FDG activity in early phase imaging is not essentially benign. Clin Nucl Med 33 (2008) 931-933
57. Fuster D., Chiang S., Andreadis C., et al. Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?. Nucl Med Commun 27 (2006) 11-15
58. Carr R., Barrington S.F., Madan B., et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91 (1998) 3340-3346
59. Pelosi E., Penna D., Deandreis D., et al. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging 52 (2008) 9-16